Key result
SAMβA restores mitochondrial function and improves cardiac contractility in preclinical heart failure models.
Answers are grounded in this paper and cite their sources.
Demonstrates that selective inhibition of Mfn1-βIIPKC improves cardiac contractility in rats with heart failure, suggesting a potential therapeutic target.
We previously demonstrated that beta II protein kinase C (βIIPKC) activity is elevated in failing hearts and contributes to this pathology. Here we report that βIIPKC accumulates on the mitochondrial outer membrane and phosphorylates mitofusin 1 (Mfn1) at serine 86. Mfn1 phosphorylation results in partial loss of its GTPase activity and in a buildup of fragmented and dysfunctional mitochondria in heart failure. βIIPKC siRNA or a βIIPKC inhibitor mitigates mitochondrial fragmentation and cell death. We confirm that Mfn1-βIIPKC interaction alone is critical in inhibiting mitochondrial function and cardiac myocyte viability using SAMβA, a rationally-designed peptide that selectively antagonizes Mfn1-βIIPKC association. SAMβA treatment protects cultured neonatal and adult cardiac myocytes, but not Mfn1 knockout cells, from stress-induced death. Importantly, SAMβA treatment re-establishes mitochondrial morphology and function and improves cardiac contractility in rats with heart failure, suggesting that SAMβA may be a potential treatment for patients with heart failure.
No takes yet. Share an insight, caveat, or question.
Ferreira et al. (2019) studied Heart failure. SAMβA (selective inhibitor of Mfn1-βIIPKC association) was evaluated on Mitochondrial morphology and function, and cardiac contractility. SAMβA selectively antagonized Mfn1-βIIPKC association, re-establishing mitochondrial morphology and function and improving cardiac contractility in rats with heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: